False-negative 123I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease

Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma

(2011) G. Eisenhofer et al.   CLINICAL CHEMISTRY

Functional Imaging ofSDHx-Related Head and Neck Paragangliomas: Comparison of18F-Fluorodihydroxyphenylalanine,18F-Fluorodopamine,18F-Fluoro-2-Deoxy-d-Glucose PET,123I-Metaiodobenzylguanidine Scintigraphy, and111In-Pentetreotide Scintigraphy

(2011) Kathryn S. King et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma

(2011) Iñaki Comino-Méndez et al.   NATURE GENETICS

Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma

(2010) Erik F. Hensen et al.   Familial Cancer

123I-Meta-Iodobenzylguanidine Scintigraphy for the Detection of Neuroblastoma and Pheochromocytoma: Results of a Meta-Analysis

(2010) Arnold F. Jacobson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

6-18F-Fluoro-l-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to123I-Metaiodobenzyl-Guanidine Scintigraphy in the Detection of Extraadrenal and Hereditary Pheochromocytomas and Paragangliomas: Correlation with Vesicular Monoamine Transporter Expression

(2010) C. Fottner et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Utility of Metaiodobenzylguanidine Single Photon Emission Computed Tomography/Computed Tomography (MIBG SPECT/CT) for the Diagnosis of Pheochromocytoma

(2009) Goswin Y. Meyer-Rochow et al.   ANNALS OF SURGICAL ONCOLOGY

Clinical Predictors and Algorithm for the Genetic Diagnosis of Pheochromocytoma Patients

(2009) Z. Erlic et al.   CLINICAL CANCER RESEARCH

Update on nuclear medicine imaging of neuroendocrine tumors

(2009) Stanley J Goldsmith   Future Oncology

Comparison of18F-Fluoro-L-DOPA,18F-Fluoro-Deoxyglucose, and18F-Fluorodopamine PET and123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma

(2009) Henri J. L. M. Timmers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinically Guided Genetic Screening in a Large Cohort of Italian Patients with Pheochromocytomas and/or Functional or Nonfunctional Paragangliomas

(2009) Massimo Mannelli et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

6-[F-18]Fluoro-l-Dihydroxyphenylalanine Positron Emission Tomography Is Superior to Conventional Imaging with123I-Metaiodobenzylguanidine Scintigraphy, Computer Tomography, and Magnetic Resonance Imaging in Localizing Tumors Causing Catecholamine Excess

(2009) Helle-Brit Fiebrich et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Succinate Dehydrogenase Genetic Testing in a Large Prospective Series of Patients with Paragangliomas

(2009) Nelly Burnichon et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Phase II Study of High-Dose [131I]Metaiodobenzylguanidine Therapy for Patients With Metastatic Pheochromocytoma and Paraganglioma

(2009) Sara Gonias et al.   JOURNAL OF CLINICAL ONCOLOGY

Usefulness of 123I-MIBG Scintigraphy in the Evaluation of Patients with Known or Suspected Primary or Metastatic Pheochromocytoma or Paraganglioma: Results from a Prospective Multicenter Trial

(2009) G. A. Wiseman et al.   JOURNAL OF NUCLEAR MEDICINE

123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation

(2008) Kunwar S. S. Bhatia et al.   CLINICAL ENDOCRINOLOGY

Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO)

(2008) Henri J. L. M. Timmers et al.   CLINICAL ENDOCRINOLOGY

The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors

(2008) Saila Kauhanen et al.   ENDOCRINE-RELATED CANCER